Core Viewpoint - The article discusses the unusual behavior of Baolai Convertible Bonds, which have not undergone a price adjustment for over five years and have recently proposed a minor adjustment to the conversion price, raising questions about the rationale behind this decision [1][2]. Group 1: Baolai Convertible Bonds - The conversion price of Baolai Convertible Bonds was adjusted from 23.97 yuan to 23.8 yuan, representing a decrease of 0.71% [1]. - The conversion value increased from 63.33 to 63.78, also reflecting a 0.71% increase [1]. - The current premium rate of the convertible bonds exceeds 100%, indicating that the adjustment is not aimed at promoting conversion [1]. Group 2: Holder Information - Recent analysis of the top ten holders of Baolai Convertible Bonds shows significant changes, with Shenzhen Linyuan Investment Management reducing its holdings by 21.94 million shares, a decrease of 10.02% [2]. - Other notable holders include Ding Bixia and Zhang Peng, with changes in their holdings of 2.30 million shares and 11.32 million shares, respectively [2]. Group 3: Market Context - The article compares Baolai's situation to that of Lanfan, which faced redemption pressure, while Baolai's bond price has remained above 125 without such pressure [1][2]. - Other convertible bonds mentioned include those from Ruike and Lanfan, with Ruike proposing a price adjustment and Lanfan nearing a significant adjustment [2].

Core Viewpoint - The actual controller of Guangzhou Jiete Biological Filtration Co., Ltd., Yuan Jianhua, reduced his holdings in the company's convertible bonds, leading to a decrease in his combined equity stake in the company. Group 1: Equity Change Details - On January 7, 2026, Yuan Jianhua reduced his holdings by 200,000 convertible bonds, which represents 4.55% of the total convertible bonds issued, totaling 4,399,430 [2][4] - This reduction caused his combined equity stake to decrease from 29.26% to 27.86%, a change of 1.40% [2][4] - The combined equity stake of the actual controller and his concerted parties decreased from 44.37% to 42.05%, a change of 2.32% due to this transaction [2][4] Group 2: Pre and Post-Change Equity Situation - Before the change, Yuan Jianhua and his concerted parties held a combined equity stake of 29.26% and 44.37%, respectively, calculated based on the higher of their direct shareholding or the convertible bonds [5] - After the change, their combined equity stakes are now 27.86% and 42.05%, respectively [6] Group 3: Transaction Nature - The equity change was a result of a bulk transaction of convertible bonds and did not trigger a mandatory tender offer, meaning there will be no change in the actual control of the company [4][7]

Core Viewpoint - The actual controller of Guangzhou Jiete Biological Filtration Co., Ltd., Yuan Jianhua, reduced his holdings in the company's convertible bonds, leading to a decrease in his overall equity stake in the company. Summary by Sections 1. Equity Change Overview - On January 7, 2026, Yuan Jianhua reduced his holdings by 200,000 convertible bonds, which represents 4.55% of the total convertible bonds issued (4,399,430 bonds) [1][2] - This reduction caused his combined equity stake in the company to decrease from 29.26% to 27.86%, a change of 1.40% [1][2] - The combined equity stake of the actual controller and his concerted parties fell from 44.37% to 42.05%, a change of 2.32% [1][2] 2. Pre- and Post-Equity Change Situation - Before the equity change, Yuan Jianhua and his concerted parties held a combined equity stake of 29.26% and 44.37%, respectively, based on the higher of the two calculations [3] - After the equity change, their combined equity stakes are now 27.86% and 42.05%, respectively [4] 3. Subsequent Matters - The equity change was executed through a block trade of convertible bonds and did not trigger a mandatory tender offer, ensuring that there will be no change in the actual control of the company [2][4]

Core Viewpoint - The announcement details the conversion results and share changes related to the convertible bonds issued by Guangzhou Jet Biofiltration Co., Ltd, indicating minimal conversion activity since issuance. Group 1: Convertible Bond Issuance and Terms - The company issued 4.4 million convertible bonds with a face value of RMB 100 each, raising a total of RMB 44 million, with a maturity period from June 28, 2022, to June 27, 2028 [3] - The convertible bonds, named "Jet Convertible Bonds," began trading on the Shanghai Stock Exchange on August 2, 2022, under the code "118010" [3] - The conversion price was set at RMB 48.23 per share starting January 4, 2023 [3] Group 2: Conversion Status - As of December 31, 2025, a total of RMB 57,000 had been converted into 1,185 shares, representing 0.00084% of the total shares before conversion [2][5] - No bonds were converted between October 1, 2025, and December 31, 2025, with a total conversion amount of RMB 0.00 [2][5] - The remaining unconverted bonds amounted to RMB 439,943,000, which is 99.9870% of the total issuance [2][6] Group 3: Adjustments to Conversion Price - The conversion price was adjusted from RMB 48.23 to RMB 48.09 on June 6, 2023, due to the completion of the first vesting period of the 2021 restricted stock incentive plan [4] - Further adjustments to the conversion price are scheduled, with a decrease to RMB 48.02 on July 4, 2024, and to RMB 47.95 on July 2, 2025, as part of annual equity distribution plans [4]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock price performance [6][11]. Group 1: Board Meeting Decisions - The fourth board meeting of the company was held on November 21, 2025, with all seven directors present, and the decision was made to not adjust the conversion price of the "Jiet Bio" convertible bonds [1][2]. - The decision was made with a vote of 4 in favor, 0 against, and 0 abstentions [2]. Group 2: Convertible Bond Details - The "Jiet Bio" convertible bonds were issued in 2022, with a total of 4.4 million bonds at a face value of 100 RMB each, raising a total of 440 million RMB [8]. - The initial conversion price was set at 48.23 RMB per share, which has been adjusted multiple times due to various corporate actions [9]. Group 3: Price Adjustment Clause - The downward adjustment clause for the conversion price is triggered when the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - As of the announcement date, the stock price had indeed triggered this clause, but the board decided against making any adjustments for the next three months [11].

Core Viewpoint - The company is potentially triggering a downward adjustment of the conversion price for its convertible bonds due to stock prices falling below a specified threshold, which may impact investor decisions and the company's financial strategy [2][8]. Convertible Bond Issuance - The company issued a total of 4.4 million convertible bonds with a face value of 100 RMB each, raising a total of 440 million RMB, with a maturity period from June 28, 2022, to June 27, 2028 [2][3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and will further adjust to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025, due to annual equity distribution plans [3][4]. Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5][6]. - The potential trigger for this adjustment is set to begin on November 3, 2025, with a threshold price of 40.76 RMB per share [8]. Adjustment Procedure - If the company decides to adjust the conversion price, it will announce the details, including the adjustment range and the record date for shareholders, through the Shanghai Stock Exchange [7].

Core Points - Jiet Bio announced that from November 3 to November 14, 2025, its stock has closed below 85% of the current conversion price for 10 trading days, which is expected to trigger the downward adjustment of the conversion price [1] - If the downward adjustment clause for "Jiet Convertible Bonds" is triggered, the company's board will convene to decide whether to exercise the downward adjustment rights and will fulfill its information disclosure obligations in a timely manner [1]

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB [3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and further adjusted to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025 [4]. - The downward adjustment clause is triggered when the stock price is below 85% of the conversion price for at least 15 out of 30 consecutive trading days [5]. Group 2: Board Decision - The board of directors convened on August 1, 2025, and unanimously agreed not to adjust the conversion price, with all related directors abstaining from the vote [8][9]. - The decision will remain in effect for three months, until November 1, 2025, during which time the company will not propose any downward adjustment even if the clause is triggered again [7][9].

Group 1 - The company held its 22nd meeting of the 4th Board of Directors on August 1, 2025, with all 7 participating directors voting unanimously [1] - The Board approved the proposal not to lower the conversion price of the "Jietai Convertible Bonds," with 4 votes in favor and no opposition or abstentions [1] - Related directors recused themselves from the voting process [1] Group 2 - The company will not propose a downward adjustment to the conversion price within the next three months, from now until November 1, 2025 [2] - If the conversion price adjustment clause is triggered again after November 2, 2025, the Board will reconvene to decide on the adjustment [2] - Further details are available in the announcement published on the Shanghai Stock Exchange website [2]

Core Viewpoint - The company, JieTe Bio, announced that its board of directors has approved a proposal not to lower the conversion price of its convertible bonds, known as "JieTe Convertible Bonds" [2] Group 1 - The fourth meeting of the fourth board of directors took place on August 1, where the proposal was reviewed and approved [2]